Paclitaxel News and Research

RSS

Paclitaxel is a drug used to treat breast cancer, ovarian cancer, and AIDS-related Kaposi sarcoma. It is also used together with another drug to treat non-small cell lung cancer. Paclitaxel is also being studied in the treatment of other types of cancer. It blocks cell growth by stopping cell division and may kill cancer cells. It is a type of antimitotic agent. Also called Taxol.

The Paclitaxel compound is extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity. Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). Check for active clinical trials or closed clinical trials using this agent.

Chemotherapy may reduce HIV-infected T cells

Advancements in HIV/AIDS research, drug development and clinical practice since the 1980s have made it possible for people living with HIV to lead long, productive lives and keep the virus in check at undetectable levels and nontransmissible as long as therapy is maintained.

15 Dec 2025

Preoperative radiation may enhance treatment response in patients with HR-positive, HER2-negative breast cancer

Preoperative radiation improved T-cell infiltration (TCI) in patients with hormone receptor (HR)-positive, HER2-negative breast cancer when administered in combination with pembrolizumab (Keytruda) and chemotherapy and led to improved treatment responses prior to surgery, according to the results of the phase II P-RAD clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9-12, 2025.

11 Dec 2025

Study shines new light on how cancer avoids the mitotic stopwatch pathway

When cell division (mitosis) takes too long, it can be a sign that something is wrong with the cells, for example DNA damage or chromosomal instability.

10 Dec 2025

Cell nucleus shape plays a key role in cancer therapy outcomes

Cancer cells with a cell nucleus that is easily deformed are more sensitive to drugs that damage DNA. These are the findings of a new study by researchers at Linköping University in Sweden.

2 Dec 2025

Scientists uncover molecular mechanism behind chemotherapy-induced peripheral neuropathy

Chemotherapy activates a stress sensor in immune cells, triggering inflammation and nerve damage, which may help explain why many cancer patients experience debilitating pain as a side effect, according to a new study by Weill Cornell Medicine and Wake Forest University School of Medicine researchers

20 Nov 2025

Innovative CRISPR strategy resensitizes lung cancer to treatment

In a major step forward for cancer care, researchers at ChristianaCare's Gene Editing Institute have shown that disabling the NRF2 gene with CRISPR technology can reverse chemotherapy resistance in lung cancer.

17 Nov 2025

Sirolimus-eluting balloon emerges as a safe and effective option for coronary in-stent restenosis

A new drug-eluting balloon can perform just as well as the standard treatment for patients with coronary in-stent restenosis (ISR) undergoing repeated percutaneous coronary intervention (PCI).

31 Oct 2025

Scientists uncover why many cancer patients develop chemotherapy-induced neuropathy

Scientists at Wake Forest University School of Medicine, in collaboration with researchers at Weill Cornell Medicine, have made a breakthrough in understanding why many cancer patients develop nerve damage after chemotherapy.

30 Oct 2025

Bottlebrush particles deliver large range of chemotherapy drugs directly to tumor cells

Using tiny particles shaped like bottlebrushes, MIT chemists have found a way to deliver a large range of chemotherapy drugs directly to tumor cells.

10 Sep 2025

Exploring whether chemotherapy disrupts biological clock in the brain to impair circadian rhythms

During and after chemotherapy, nearly half of cancer patients endure circadian rhythm disruptions, which worsens treatment side effects.

9 Sep 2025

Adjuvant chemo-immunotherapy may benefit patients with resected stage IB–IIIA NSCLC, trial suggests

Interim results from the NADIM ADJUVANT Phase III trial, led by the Spanish Lung Cancer Group (GECP), suggest that adjuvant chemo-immunotherapy may reduce the risk of recurrence in patients with completely resected stage IB–IIIA non-small cell lung cancer (NSCLC) while maintaining an acceptable safety profile.

8 Sep 2025

Natural medicines as emerging tools to target the tumor vascular microenvironment

Recent advances in cancer treatment highlight the potential of natural medicines to target the tumor vascular microenvironment, offering a novel strategy to inhibit tumor growth and metastasis.

5 Sep 2025

Drug-coated devices not associated with improved outcomes in patients with peripheral artery disease

Drug-coated stents and balloons were not associated with reduced risk of amputation or improved quality of life compared with uncoated devices in two trials in peripheral artery disease (PAD), according to late-breaking research presented in a Hot Line session today at ESC Congress 2025.

1 Sep 2025

New formulation of chemotherapy drug opens doors to advanced cancer treatment options

University of Arizona researchers devised a new method to deliver cancer chemotherapy drugs to pancreatic and breast cancer tumors more effectively and with less damage to healthy tissues than standard forms of chemotherapy.

21 Aug 2025

New approach doubles chemotherapy effectiveness by targeting cancer cell memory

In a wholly new approach to cancer treatment, Northwestern University biomedical engineers have doubled the effectiveness of chemotherapy in animal experiments.

22 Jul 2025

KAIST scientists develop tool to fight drug resistance in cancer

One of the biggest obstacles in cancer treatment is drug resistance in cancer cells. Conventional efforts have focused on identifying new drug targets to eliminate these resistant cells, but such approaches can often lead to even stronger resistance.

8 Jul 2025

Study finds overlap between chemotherapy side effects and brain aging

While chemotherapy can be lifesaving, it also damages DNA and leads to cognitive issues known as "chemo brain." These effects resemble the memory and learning problems seen in older adults, prompting University of Oklahoma researchers to investigate this unique overlap of cognitive decline.

26 Jun 2025

New DNA test predicts chemotherapy resistance in cancer patients

Cancer Research UK-funded scientists at the University of Cambridge, in collaboration with the Spanish National Cancer Research Centre (CNIO) and Cambridge-based startup Tailor Bio, have created a test which can successfully predict whether cancer will resist common forms of chemotherapy treatment.

23 Jun 2025

THP regimen achieves high response rates in HER2 positive breast cancer patients

Patients with Stage II and III (early-stage) HER2+ breast cancer usually undergo pre-operative therapy with multi-agent chemotherapy in combination with anti-HER2 antibodies, followed by surgery.

2 Jun 2025

New treatment option for advanced thymic carcinoma shows promise

Thymic epithelial tumors are a rare group of malignancies originating in the thymus gland, that includes thymoma and thymic carcinoma.

12 Mar 2025